Pharmacology Laboratory, Institute of Research for Food Safety and Health IRC-FSH, Department of Health Sciences, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy.
Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Int J Mol Sci. 2023 Dec 22;25(1):191. doi: 10.3390/ijms25010191.
Obesity is one of the world's most serious public health issues, with a high risk of developing a wide range of diseases. As a result, focusing on adipose tissue dysfunction may help to prevent the metabolic disturbances commonly associated with obesity. Nutraceutical supplementation may be a crucial strategy for improving WAT inflammation and obesity and accelerating the browning process. The aim of this study was to perform a preclinical "proof of concept" study on , an innovative formulation originating from a combination of bergamot polyphenolic fraction (BPF) and (CyC), for the treatment of adipose tissue dysfunction. In particular, supplementation in WD/SW-fed mice at doses of 50 mg/kg given orally for 12 weeks, was able to reduce body weight and total fat mass in the WD/SW mice, in association with an improvement in plasma biochemical parameters, including glycemia, total cholesterol, and LDL levels. In addition, a significant reduction in serum ALT levels was highlighted. The decreased WAT levels corresponded to an increased weight of BAT tissue, which was associated with a downregulation of PPARγ as compared to the vehicle group. was able to restore PPARγ levels and prevent NF-kB overexpression in the WAT of mice fed a WD/SW diet, suggesting an improved oxidative metabolism and inflammatory status. These results were associated with a significant potentiation of the total antioxidant status in WD/SW mice. Finally, our data show, for the first time, that supplementation may be a valuable approach to counteract adipose tissue dysfunction and obesity-associated effects on cardiometabolic risk.
肥胖是全球最严重的公共卫生问题之一,存在多种疾病的高风险。因此,关注脂肪组织功能障碍可能有助于预防与肥胖相关的代谢紊乱。营养保健品的补充可能是改善 WAT 炎症和肥胖并加速褐色化过程的关键策略。本研究旨在对一种源自佛手柑多酚部分(BPF)和环孢菌素(CyC)组合的创新制剂进行临床前“概念验证”研究,用于治疗脂肪组织功能障碍。特别是,在 WD/SW 喂养的小鼠中,以 50mg/kg 的剂量经口给予 12 周的补充剂,能够降低 WD/SW 小鼠的体重和总脂肪量,同时改善血浆生化参数,包括血糖、总胆固醇和 LDL 水平。此外,还强调了血清 ALT 水平的显著降低。与载体组相比,WAT 水平的降低对应于 BAT 组织重量的增加,这与 PPARγ 的下调有关。补充剂能够恢复 WD/SW 饮食喂养的小鼠的 WAT 中的 PPARγ 水平并预防 NF-kB 的过度表达,表明氧化代谢和炎症状态得到改善。这些结果与 WD/SW 小鼠总抗氧化状态的显著增强有关。最后,我们的数据首次表明,补充剂可能是一种有价值的方法,可以对抗脂肪组织功能障碍和肥胖相关的对心脏代谢风险的影响。